About
Pricing
FAQs
Providers
Trials
Blog
Back to your record
Login
Get started
Finding studies
Search
Narrow
Order
Status
Recruiting
Not yet recruiting
Active, not recruiting
Enrolling by invitation
Completed
Terminated
Phase
Early phase 1
Phase 1
Phase 1–2
Phase 2
Phase 2–3
Phase 3
Phase 4
Not applicable
Who can join
Healthy volunteers too
Searching
1–20 of 3,597
Completed
Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma
This is a phase II study of the combination of Avastin and metronomic temozolomide in recurrent malignant glioma patients.
NCT00501891
·
Durham, North Carolina
Terminated
Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells, but also damages normal cells in the developing brains of children.
NCT00031590
·
Palo Alto, California and 2 others
Completed
Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma
Increasing preclinical and clinical data have shown that myeloid-derived suppressor cells (MDSCs) may represent a significant driver of immunosuppression in glioblastoma (GBM…
NCT04757662
·
St Louis, Missouri
Suspended
A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG)
Current therapies for diffuse, intrinsic pontine glioma (DIPG) provide very limited benefit to the patient.
NCT02742883
·
Houston, Texas
Unknown
Vitamin D for Treatment of Glioblastoma Multiforme
This is non-randomized phase 2 study to assess efficacy and toxicity of long term high dose vitamin D3 given concurrently with chemo-radiotherapy (CCRT) containing temozolomide…
NCT01181193
·
Beersheba
Unknown
Immunohistochemical Assessment of Programmed Death ligand1 and LC3B in GBM
Glioblastoma(GBM) is the most common malignant primary brain tumor and has unfortunately bad prognosis .PDL(Programmed death lignad 1)1 is alignad for a protein receptor…
NCT04284306
Completed
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
This is a multicenter, open label, Phase 1 dose-escalation study of DSP-7888 Dosing Emulsion administered to adult patients with advanced malignancies.
NCT02498665
·
Denver, Colorado and 7 others
Terminated
Incidence of Intracranial Hemorrhage in Glioma Patients With Venous Thromboembolism Converted From LMWH to Apixaban
Glioma patients with history of venous thromboembolism (VTE) treated on low molecular weight heparin (LMWH) and who decided with their physician to convert to Apixaban (oral drug)…
NCT04895553
·
Sacramento, California and 1 other
Terminated
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
This is an adaptive design, randomized controlled, Phase 3 clinical trial in patients with glioblastoma multiforme (GBM) or gliosarcoma (GS), previously treated with surgery (if…
NCT03149575
·
Los Angeles, California and 4 others
Terminated
Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Gene therapy may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy.
NCT00003567
·
Cleveland, Ohio
No longer available
SurVaxM Expanded Access Protocol
Data from clinical trials suggest that SurVaxM administered as a single agent, or in combination with standard glioblastoma chemotherapy treatment regimens to patients with…
NCT04802447
Recruiting
Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-Being
The goal of this clinical trial is to learn if the newly designed group self-management program is feasible to conduct and improves mental and behavioral health outcomes compared…
NCT07628647
·
Aurora, Colorado and 1 other
Recruiting
FUS Etoposide for DMG
The blood brain barrier (BBB) prevents some drugs from successfully reaching the target tumor.
NCT05762419
·
New York, New York
Recruiting
MRS of Glioma Genomics
In France, about 5000 new people with a primary malignant brain tumor are diagnosed each year.
NCT05700071
·
Paris and 1 other
Completed
Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma
TVI-Brain-1 is an experimental treatment that takes advantage of the fact that your body can produce immune cells, called 'killer' white blood cells that have the ability to kill…
NCT01290692
·
Kansas City, Missouri and 3 others
Terminated
Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM
A glioblastoma (GBM) is the most common malignant primary brain tumor, yet it is not easy to control.
NCT02085304
·
Phoenix, Arizona
Withdrawn
Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma
The primary aim of this study is to determine the presence of gemcitabine in childhood diffuse midline gliomas (DMG) (previously classified as diffuse intrinsic pontine glioma…
NCT04051047
·
Ann Arbor, Michigan
Unknown
FKBP51s: a New Molecular Biomarker for Glioblastoma? Pre- and Post-operative Blood Levels Evaluation of FKBP51s Protein and Correlation With MRI Phenotype
The aim of this interventional study is to investigate the correlation between Magnetic Resonance Phenotype and levels of FKBP51s protein pre and post surgery in adult patients…
NCT05793021
·
Roma
Completed
Neoadjuvant Nivolumab in Glioblastoma
Neoadjuvant nivolumab will be administered to patients with primary and recurrent glioblastoma multiforme that require surgery. Nivolumab will be continued following surgery.
NCT02550249
·
Pamplona, Navarre
Not yet recruiting
Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG
The goal of this study is to further evaluate feasibility and tolerability of Opdualag for patients with replication repair deficient HGG, including DIPG.
NCT07644312
Back
1
2
3
···
180
1 / 180
Next
Data from
ClinicalTrials.gov
Terms
